Back to Search Start Over

Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment

Authors :
Craig J. Galbán
Theodore S. Lawrence
Thomas L. Chenevert
Charles R. Meyer
Judith S. Sebolt-Leopold
Alnawaz Rehemtulla
Christina Tsien
Daniel A. Hamstra
Brian D. Ross
Pia C. Sundgren
Timothy D. Johnson
Stefanie Galbán
Larry Junck
Source :
Clinical Cancer Research. 17:4751-4760
Publication Year :
2011
Publisher :
American Association for Cancer Research (AACR), 2011.

Abstract

Purpose: Currently, radiologic response of brain tumors is assessed according to the Macdonald criteria 10 weeks from the start of therapy. There exists a critical need to identify nonresponding patients early in the course of their therapy for consideration of alternative treatment strategies. Our study assessed the effectiveness of the parametric response map (PRM) imaging biomarker to provide for an earlier measure of patient survival prediction. Experimental Design: Forty-five high-grade glioma patients received concurrent chemoradiation. Quantitative MRI including apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired pretreatment and 3 weeks midtreatment on a prospective institutional-approved study. PRM, a voxel-by-voxel image analysis method, was evaluated as an early prognostic biomarker of overall survival. Clinical and conventional MR parameters were also evaluated. Results: Multivariate analysis showed that PRMADC+ in combination with PRMrCBV− obtained at week 3 had a stronger correlation to 1-year and overall survival rates than any baseline clinical or treatment response imaging metric. The composite biomarker identified three distinct patient groups, nonresponders [median survival (MS) of 5.5 months, 95% CI: 4.4–6.6 months], partial responders (MS of 16 months, 95% CI: 8.6–23.4 months), and responders (MS has not yet been reached). Conclusions: Inclusion of PRMADC+ and PRMrCBV− into a single imaging biomarker metric provided early identification of patients resistant to standard chemoradiation. In comparison to the current standard of assessment of response at 10 weeks (Macdonald criteria), the composite PRM biomarker potentially provides a useful opportunity for clinicians to identify patients who may benefit from alternative treatment strategies. Clin Cancer Res; 17(14); 4751–60. ©2011 AACR.

Details

ISSN :
15573265 and 10780432
Volume :
17
Database :
OpenAIRE
Journal :
Clinical Cancer Research
Accession number :
edsair.doi...........5965d93fd7bfe00f2ef37d427aca5bb5
Full Text :
https://doi.org/10.1158/1078-0432.ccr-10-2098